Skip to Content
Merck
  • A novel truncated form of apolipoprotein A-I transported by dense LDL is increased in diabetic patients.

A novel truncated form of apolipoprotein A-I transported by dense LDL is increased in diabetic patients.

Journal of lipid research (2015-07-15)
Judit Cubedo, Teresa Padró, Maisa García-Arguinzonis, Gemma Vilahur, Inka Miñambres, Jose María Pou, Juan Ybarra, Lina Badimon
ABSTRACT

Diabetic (DM) patients have exacerbated atherosclerosis and high CVD burden. Changes in lipid metabolism, lipoprotein structure, and dysfunctional HDL are characteristics of diabetes. Our aim was to investigate whether serum ApoA-I, the main protein in HDL, was biochemically modified in DM patients. By using proteomic technologies, we have identified a 26 kDa ApoA-I form in serum. MS analysis revealed this 26 kDa form as a novel truncated variant lacking amino acids 1-38, ApoA-IΔ(1-38). DM patients show a 2-fold increase in ApoA-IΔ(1-38) over nondiabetic individuals. ApoA-IΔ(1-38) is found in LDL, but not in VLDL or HDL, with an increase in LDL3 and LDL4 subfractions. To identify candidate mechanisms of ApoA-I truncation, we investigated potentially involved enzymes by in silico data mining, and tested the most probable molecule in an established animal model of diabetes. We have found increased hepatic cathepsin D activity as one of the potential proteases involved in ApoA-I truncation. Cathepsin D-cleaved ApoA-I exhibited increased LDL binding affinity and decreased antioxidant activity against LDL oxidation. In conclusion, we show for the first time: a) presence of a novel truncated ApoA-I form, ApoA-IΔ(1-38), in human serum; b) ApoA-IΔ(1-38) is transported by LDL; c) ApoA-IΔ(1-38) is increased in dense LDL fractions of DM patients; and d) cathepsin D-ApoA-I truncation may lead to ApoA-IΔ(1-38) binding to LDLs, increasing their susceptibility to oxidation and contributing to the high cardiovascular risk of DM patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Chloroform, ACS reagent, ≥99.8%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
Methanol, anhydrous, 99.8%
Sigma-Aldrich
Chloroform, anhydrous, contains amylenes as stabilizer, ≥99%
Sigma-Aldrich
Chloroform, anhydrous, ≥99%, contains 0.5-1.0% ethanol as stabilizer
Supelco
Chloroform, suitable for HPLC, ≥99.8%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
Methanol, suitable for HPLC, gradient grade, 99.93%
Sigma-Aldrich
Chloroform, ACS reagent, ≥99.8%, contains amylenes as stabilizer
Sigma-Aldrich
Chloroform, ≥99%, PCR Reagent, contains amylenes as stabilizer
Sigma-Aldrich
Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe, ≥97% (HPLC)
Sigma-Aldrich
Methanol, HPLC Plus, ≥99.9%, poly-coated bottles
Sigma-Aldrich
Methanol, JIS 300, ≥99.8%, for residue analysis
Sigma-Aldrich
Chloroform, JIS 300, ≥99.0%, for residue analysis
Sigma-Aldrich
Chloroform, SAJ super special grade, ≥99.0%
Sigma-Aldrich
Chloroform, SAJ first grade, ≥99.0%, contains 0.4-0.8% ethanol
Sigma-Aldrich
Methanol, SAJ special grade
Sigma-Aldrich
Chloroform, suitable for HPLC
Sigma-Aldrich
Chloroform, JIS special grade, ≥99.0%
Sigma-Aldrich
Methanol, suitable for HPLC
Sigma-Aldrich
Methanol, SAJ first grade, ≥99.5%
Sigma-Aldrich
Methanol, JIS special grade, ≥99.8%
Sigma-Aldrich
Methanol, NMR reference standard
Sigma-Aldrich
Methanol-12C, 99.95 atom % 12C
Sigma-Aldrich
Methanol solution, NMR reference standard, 4% in methanol-d4 (99.8 atom % D), NMR tube size 3 mm × 8 in.
Supelco
Methanol solution, contains 0.10 % (v/v) formic acid, UHPLC, suitable for mass spectrometry (MS), ≥99.5%
Sigma-Aldrich
Apolipoprotein A−I human, recombinant, expressed in E. coli, ≥97% (SDS-PAGE), ≥97% (HPLC)
Sigma-Aldrich
Anti-Apolipoprotein A-I Rabbit pAb, liquid, Calbiochem®
Sigma-Aldrich
Apolipoprotein A−I human, histidine-tagged, recombinant, expressed in HEK 293 cells, ≥98% (SDS-PAGE), lyophilized powder